Lv2
104 积分 2025-10-15 加入
Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC
2天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
13天前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
13天前
已完结
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer
14天前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
14天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
14天前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
14天前
已完结
Improving sleep in severe CRSwNP: an RCT on the effect of mepolizumab and FESS on OSA, sleep disturbances and quality of life
15天前
已完结
The pathobiology and treatment of mucus plugs in asthma and COPD: state of the art
15天前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
27天前
已完结
皖公网安备34019202002308
